Lifetime survival and medical costs of lung cancer: a semi-parametric estimation from South Korea

Park, Hae Young; Hwang, Jinseub; Kim, Do Hyang; Jeon, Soo Min; Choi, Sun Ha; Kwon, Jin-Won

doi:10.1186/s12885-020-07353-8

Cited by 5 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the South Korean study, the estimated survival times during 120 months of follow‐up were 7.8 years for the surgery group and 2.8 years for the chemotherapy and/or radiotherapy group. The surgery group was associated with the highest medical expenditure in the first year after diagnosis, although the estimated overall mean annual cost decreased in the following order: chemotherapy and/or radiotherapy; surgery plus chemotherapy and/or radiotherapy; and surgery 24 . In our study, the mean age in the resection group was 73 years and in the drug or radiation group was 74 years.…”

Section: Discussioncontrasting

confidence: 45%

“…The surgery group was associated with the highest medical expenditure in the first year after diagnosis, although the estimated overall mean annual cost decreased in the following order: chemotherapy and/or radiotherapy; surgery plus chemotherapy and/or radiotherapy; and surgery. 24 In our study, the mean age in the resection group was 73 years and in the drug or radiation group was 74 years. Because of the characteristics of DB, patients in our study were older than in previous studies (77.8% of the surgery group and 60.2% of the medically treated group were under 75 years in the Spanish study; 63.7 and 65.8 years, respectively, in the surgery only group and chemo and/or radiotherapy group in the Korean study).…”

Section: Discussionmentioning

confidence: 55%

“…Using approaches similar to the present study, researchers in Spain 23 and South Korea 24 evaluated the impacts of lung cancer treatment on survival and medical expenditures. In the Spanish study, the 30‐month mortality rates were 79.3 and 24.4% for medically and surgically treated patients, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Survival and medical costs of non‐small cell lung cancer patients according to the first‐line treatment: An observational study using the Kyoto City Integrated Database

et al. 2023

View full text Add to dashboard Cite

Background Lung cancer is the primary cause of cancer mortality and non‐small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases. New drug treatments have been developed since 2010 but there are concerns about the increase in medical costs. This study aimed to compare survival and medical costs among patients with NSCLC according to their initial treatment to estimate the impact of early NSCLC detection. Methods Patients with primary NSCLC who filed insurance claims between April 2013 and March 2019 were identified using the Kyoto City Integrated Database. Patients were divided into two groups depending on their initial treatment: the resection group and drug or radiation group. The survival and medical costs were calculated. Results A total of 2609 patients with primary NSCLC were identified. Among them, 1035 patients underwent resection. The 5‐year survival was 75% for the resection group while below 25% for the drug or radiation group. At 6 months of survival, the median cumulative total cost was 2409 thousand yen (interquartile range [IQR] 1947–4012 thousand yen) in the resection group and 2951 thousand yen (IQR 1600–4706 thousand yen) in the drug or radiation group. At 4 years of survival, the cumulative median total cost was 5257 thousand yen (IQR 3808–8243 thousand yen) in the resection group and 10 202 thousand yen (IQR 4845–20 450 thousand yen) in the drug or radiation group. Conclusions As a first‐line therapy in newly diagnosed patients with NSCLC, surgical resection is associated with longer survival and lower medical costs than pharmacotherapy or radiotherapy.

show abstract

Section: Discussioncontrasting

confidence: 45%

Section: Discussionmentioning

confidence: 55%

See 1 more Smart Citation

Survival and medical costs of non‐small cell lung cancer patients according to the first‐line treatment: An observational study using the Kyoto City Integrated Database

et al. 2023

View full text Add to dashboard Cite

show abstract

“…12,23 The validity and applicability of this method on the Korean population has been tested and proved in other articles as well. 6,31 Moreover, the accuracy of the mortality rate of the simulated referents has been improved in the most recent version of the iSQoL2 package by adopting the cohort life International Journal of Stroke, 18 (7) expectancy (CLE) instead of the period life expectancy (PLE). Using the existing real-world data from the past several decades, CLE would be more accurate for estimating the average life expectancy at a given age.…”

Section: Discussionmentioning

confidence: 99%

The lifetime burden following stroke: Long term impact of stroke on survival and quality of life

Cheon

Jeng

et al. 2023

International Journal of Stroke

View full text Add to dashboard Cite

Background The absolute burden of stroke in Korea is ever growing. Many studies have explored the outcomes of mortality, quality of life (QOL), and/or economic burden with limited periods of observation. Relatively few have addressed the lifetime outcomes that are estimated beyond the limited observation period of study samples. Aims By combining QOL and the survival functions over a lifetime horizon, our aims were to estimate the quality-adjusted life expectancy (QALE) and loss-of-QALE of patients with ischemic and hemorrhagic stroke in South Korea, and to compare them between genders. Methods The survival function of stroke patients (n=13,994) was estimated by the Kaplan-Meier’s method from the National Health Insurance Service-National Sample Cohort of Korea (2002-2015), and then extrapolated to lifetime through a rolling-over algorithm. The QOL measurements, assessed by EuroQol 5-dimension (EQ-5D) questionnaire, of stroke patients (n=474) were extracted from the Korea Health Panel (KHP, 2008-2018) to estimate the QALE. All stroke patients were categorized by sex and two types of stroke: ischemic and hemorrhagic. Age-, sex-, and calendar year-matched referents were simulated from the Korean life tables to be integrated with the general population’s QOL from the KHP to estimate the QALE of the referents. We calculated the loss-of-QALE by comparing the above two sets of QALE. Results The QALE and loss-of-QALE for ischemic stroke were 10.8 and 6.1 QALYs (quality-adjusted life years), respectively, and 14.0 and 9.0 QALYs for hemorrhagic stroke. The loss-of-QALE in men was 3.0 QALYs larger than that of women with hemorrhagic stroke (p < 0.05), while the difference for ischemic stroke was much smaller and statistically insignificant at 0.6 QALYs. Conclusions The lifetime impact of stroke in Korea is large, especially for males who survived hemorrhagic stroke. Future studies assessing the lifetime needs for long-term care of stroke patients are warranted to quantify the burden of stroke from the societal perspective.

show abstract

“…In contrast, the lung cancer-related anti-cancer drug therapy was noted as the major cost driver with an average 53% share across all patients [ 14 ]. Further analysis of lifetime estimates by the same authors revealed the overall mean cost per year to be 4359 USD in surgery, 7075 USD in Surgery+CTx/RTx and 7626 USD in CTx/RTx groups [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

et al. 2021

View full text Add to dashboard Cite

Background This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. Methods In this cost of illness study, direct medical cost was calculated based on cost items related to outpatient visits, laboratory and radiological tests, hospitalizations/interventions, drug treatment, adverse events and metastasis. Indirect cost was calculated based on lost productivity due to early retirement, morbidity and premature death resulting from the illness, the value of lost productivity due to time spent by family caregivers and cost of formal caregivers. Results Cost analysis revealed the total per patient annual direct medical cost for small cell lung cancer to be €8772), for non-small-cell lung cancer to be €10,167. Total annual direct medical cost was €497.9 million, total annual indirect medical cost was €1.1 billion and total economic burden of lung cancer was €1.6 billion. Hospitalization/interventions (41%) and indirect costs (68.6%) were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Conclusions Our findings indicate per patient direct medical costs of small cell lung cancer and non-small-cell lung cancer to be substantial and comparable, indicating the substantial economic burden of lung cancer in terms of both direct and indirect costs. Our findings indicate that hospitalization/interventions cost item and indirect costs were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Our findings emphasize the potential role of improved cancer prevention and early diagnosis strategies, by enabling cost savings related to drug treatment and metastasis management cost items, in sustainability of cancer treatments.

show abstract

Lifetime survival and medical costs of lung cancer: a semi-parametric estimation from South Korea

Cited by 5 publications

References 29 publications

Survival and medical costs of non‐small cell lung cancer patients according to the first‐line treatment: An observational study using the Kyoto City Integrated Database

Survival and medical costs of non‐small cell lung cancer patients according to the first‐line treatment: An observational study using the Kyoto City Integrated Database

The lifetime burden following stroke: Long term impact of stroke on survival and quality of life

Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

Contact Info

Product

Resources

About